Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Quizartinib advances overall survival in acute myeloid leukaemia patients

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma

Lack of access to new cancer medicines in LMICs

Spotlight on global cancer control at ASCO 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients